Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide in Trichotillomania
NCT07282769Phase 2Not yet recruiting
- Sponsor
- University of Chicago
- Start
- Jun 2026
- Primary completion
- Feb 2027
- Modality
- Peptides, Recombinant Proteins and Enzymes
01
Overview
A Phase 2 trial of semaglutide in trichotillomania (TTM), sponsored by University of Chicago. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
03
Conditions
trichotillomania (TTM)
Beyond the preview
Go deeper on NCT07282769.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07282769.